EMA validates Bristol Myers Squibb’s two Opdivo-based applications to treat cell carcinoma
The applications are based on positive results from the phase-III CheckMate-648 trial, in which both Opdivo-based combinations demonstrated a significant survival benefit over chemotherapy alone
Bristol Myers Squibb has announced that the European Medicines Agency (EMA) has validated its type-II variation Marketing Authorisation Applications (MAA) for both Opdivo (nivolumab) in combination with Yervoy (ipilimumab) and Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatments for adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). The validation of these applications confirms that the submissions are complete, and begins the EMA’s centralised review process, according to a company statement.
“Outcomes for patients with advanced esophageal squamous cell carcinoma treated with chemotherapy alone remain poor, and there is a clear need for additional options beyond this long-standing standard of care,” said Ian M Waxman, MD, Development Lead, Gastrointestinal Cancers, Bristol Myers Squibb.
He added, “The validation of our applications moves us a step closer to potentially bringing these two Opdivo-based regimens to patients in the EU who may benefit.”
The applications are based on results from the pivotal phase-III CheckMate-648 trial, in which both Opdivo-based treatment combinations — Opdivo plus Yervoy and Opdivo plus chemotherapy — demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit compared to chemotherapy at the pre-specified interim analysis in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) with tumour cell PD-L1 expression ≥ one per cent as well as in the all-randomised population. Opdivo plus Yervoy is the first dual immunotherapy combination to demonstrate a superior survival benefit versus chemotherapy in this setting. The safety profiles of Opdivo and chemotherapy and of Opdivo plus Yervoy were consistent with the known safety profiles of the individual components, added the statement.
It also notified that the results from CheckMate-648 were presented in an oral session during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and were selected for the official ASCO press programme.
- Advertisement -